Clinical Trial Update: ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

View source ↗

Summary

Ongoing clinical trial evaluating ctDNA-based minimal residual disease detection in patients with resected pancreatic cancer; the study is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: BAIYONG SHEN | Conditions: Pancreatic Cancer Resectable | Status: ACTIVE_NOT_RECRUITING